Last updated on February 2019

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto Respimat (AERIAL )


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Obstructive Lung Disease
  • Age: Between 40 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

Patients can be included if all of the following criteria are met:

  • Written informed consent prior to participation
  • Female and male patients 40 years of age
  • Patients diagnosed with COPD and requiring a combination of two long-acting bronchodilators (LAMA + LABA) according to approved SmPC and GOLD COPD guideline recommendation 2017 (GOLD COPD groups B to D)
  • Treatment with Spiolto Respimat acc. to SmPC at the discretion of the physician.

Exclusion Criteria:

  • Patients with contraindications according to Spiolto Respimat SmPC
  • Patients already on a LABA/LAMA combination (free and fixed dose) in the last 6 weeks before study entry
  • Patients continuing LABA-ICS treatment should not be additionally treated with Spiolto Respimat in order to avoid a double dosing of long-acting beta-agonists
  • Pregnancy and lactation
  • Current participation in any clinical trial or any other non-interventional study of a drug or device.

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.